Sunshine Guojian Pharmaceutical Shanghai Co Ltd
SSE:688336
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
SSE:688336
|
CN |
|
Elemental Royalties Corp
XTSX:ELE
|
CA |
|
Y.A.C. Holdings Co Ltd
TSE:6298
|
JP |
|
T
|
TerraVest Industries Inc
TSX:TVK
|
CA |
|
S
|
Shukra Bullions Ltd
BSE:531506
|
IN |
|
B
|
Bal Pharma Ltd
NSE:BALPHARMA
|
IN |
|
G
|
Green Planet Bio Engineering Co Ltd
OTC:GPLB
|
US |
|
E
|
Everbright Jiabao Co Ltd
SSE:600622
|
CN |
|
Koninklijke Philips NV
NYSE:PHG
|
NL |
Wall Street
Price Targets
Price Targets Summary
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
According to Wall Street analysts, the average 1-year price target for Sunshine Guojian Pharmaceutical Shanghai Co Ltd is 76.77 CNY with a low forecast of 73.69 CNY and a high forecast of 81.44 CNY.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is Sunshine Guojian Pharmaceutical Shanghai Co Ltd's stock price target?
Price Target
76.77
CNY
According to Wall Street analysts, the average 1-year price target for Sunshine Guojian Pharmaceutical Shanghai Co Ltd is 76.77 CNY with a low forecast of 73.69 CNY and a high forecast of 81.44 CNY.
What is Sunshine Guojian Pharmaceutical Shanghai Co Ltd's Revenue forecast?
Projected CAGR
15%
For the last 6 years the compound annual growth rate for Sunshine Guojian Pharmaceutical Shanghai Co Ltd's revenue is 1%. The projected CAGR for the next 3 years is 15%.
What is Sunshine Guojian Pharmaceutical Shanghai Co Ltd's Operating Income forecast?
Projected CAGR
39%
For the last 6 years the compound annual growth rate for Sunshine Guojian Pharmaceutical Shanghai Co Ltd's operating income is -7%. The projected CAGR for the next 3 years is 39%.
What is Sunshine Guojian Pharmaceutical Shanghai Co Ltd's Net Income forecast?
Projected CAGR
-8%
For the last 6 years the compound annual growth rate for Sunshine Guojian Pharmaceutical Shanghai Co Ltd's net income is 11%. The projected CAGR for the next 3 years is -8%.
